Roger Adsett - 29 Jan 2026 Form 4 Insider Report for Definium Therapeutics, Inc. (DFTX)

Role: Director
Signature: /s/ Mark Sullivan, Attorney-in-Fact for Roger Adsett
Issuer symbol: DFTX
Transactions as of: 29 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 29 Jan 2026, 20:35:22 UTC
Previous filing: 08 Jan 2026
Next filing: 04 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Adsett Roger	Director	C/O DEFINIUM THERAPEUTICS, INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK	/s/ Mark Sullivan, Attorney-in-Fact for Roger Adsett	29 Jan 2026	0001685904

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DFTX	Stock Option (Right to Buy)	Award	$0	+50,000		$0.000000	50,000	29 Jan 2026	Common Shares	50,000	$17.24	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying the option shall vest and become exercisable over a three-year period with 1/3 vesting on the first anniversary of the date of the grant and the remaining vesting in 24 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date.